WO2005095578A1 - Process for cell culturing by continuous perfusion and alternating tangential flow - Google Patents
Process for cell culturing by continuous perfusion and alternating tangential flow Download PDFInfo
- Publication number
- WO2005095578A1 WO2005095578A1 PCT/EP2005/002374 EP2005002374W WO2005095578A1 WO 2005095578 A1 WO2005095578 A1 WO 2005095578A1 EP 2005002374 W EP2005002374 W EP 2005002374W WO 2005095578 A1 WO2005095578 A1 WO 2005095578A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell culture
- cell
- process according
- perfusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/06—Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/10—Hollow fibers or tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/44—Means for regulation, monitoring, measurement or control, e.g. flow regulation of volume or liquid level
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
Definitions
- the present invention relates to perfusion culturing of cells.
- the present invention discloses a process for the culturing of cells by perfusion culturing of a cell culture comprising cell culture medium and cells, wherein cell culture medium is added to the cell culture, wherein the cell culture is circulated over a filter module comprising hollow fibers resulting in an outflow of liquid having a lower cell density than the cell culture and wherein the flow within the filter module is an alternating tangential flow. It has surprisingly been found that by perfusion culturing of animal, in particular mammalian, cells or yeast cells according to the invention, extremely high viable cell densities can be obtained, whereas the cell culture further displays an extremely high cell viability.
- the perfusion process of the invention leads to less cell aggregation in the culture, and even to a culture being a suspension of single cells without visible aggregates.
- Cell aggregation during perfusion cell culturing is disadvantageous, because process control is more difficult, due to, for example, the heterogeneity in metabolic profiles of cells within the cell aggregates. This is especially troublesome if cells form aggregates of 5 cells or more and when the aggregates comprise in total 5 % or more of the total amount of cells.
- a perfusion process is described in US 6,544,424.
- Perfusion culturing of cells has its conventional meaning in the art, i.e. it means that during culturing cells are retained by a separation device in which there is an outflow of liquid having a lower cell density than prior to separation and in which there is an inflow of the cell culture medium.
- the separation device is a filter module comprising hollow fibers.
- Perfusion culturing includes, but is not limited to continuous flow and semi- continuous flow, for example step-wise flow or staggered flow.
- With the term “hollow fiber” is meant a tubular membrane. The internal diameter of the tube is preferably between 0.3 and 6.0 mm, more preferably between 0.5 and 3.0 mm, most preferably between 0.5 and 2.0 mm.
- the mesh size in the membrane is chosen such that the size of the pores in the mesh is close to the diameter of the cells, ensuring a high retention of cells while cell debris can pass the filter.
- the mesh size is between 3-30 ⁇ m.
- Filter modules comprising hollow fibers are commercially available from for example General Electric (formerly Amersham). With "alternating tangential flow within the filter module” is meant that there is one flow in the same direction as (i.e. tangential to) the membrane surfaces of the hollow fibers, which flow is going back and forth, and that there is another flow in a direction substantially perpendicular to said filter surface. Tangential flow can be achieved according to methods known to the person skilled in the art.
- alternating tangential flow can be achieved using one pump to circulate the cell culture over a filter module comprising hollow fibers and another pump to remove the liquid having a lower cell density than prior to the filter separation.
- any type of cell culture medium suitable for the culturing of cells can in principle be used. Guidelines for choosing a cell culture medium and cell culture conditions are well known in the art and are for instance provided in Chapter 8 and 9 of Freshney, R. I. Culture of animal cells (a manual of basic techniques), 4th edition 2000, Wiley-Liss and in Doyle, A., Griffiths, J. B., Newell, D. G. Cell &Tissue culture: Laboratory Procedures 1993, John Wiley & Sons.
- a cell culture medium for mammalian cells comprises salts, amino acids, vitamins, lipids, detergents, buffers, growth factors, hormones, cytokines, trace elements and carbohydrates.
- salts include magnesium salts, for example MgCI 2 .6H 2 O, gSO 4 and MgSO 4 .7H 2 O iron salts, for example FeSO 4 .7H 2 O, potassium salts, for example KH 2 PO 4 , KCI; sodium salts, for example NaH 2 PO 4 , Na 2 HPO 4 and calcium salts, for example CaCI 2 .2H 2 O.
- amino acids are all 20 known proteinogenic amino acids, for example hystidine, glutamine, threonine, serine, methionine.
- vitamins include: ascorbate, biotin, choline.CI, myo-inositol, D-panthothenate, riboflavin.
- lipids include: fatty acids, for example linoleic acid and oleic acid; soy peptone and ethanol amine.
- detergents include Tween 80 and Pluronic F68.
- An example of a buffer is HEPES.
- growth factors/hormones/cytokines include IGF, hydrocortisone and (recombinant) insulin.
- trace elements are known to the person skilled in the art and include Zn, Mg and Se.
- carbohydrates include glucose, fructose, galactose and pyruvate.
- the pH, temperature, dissolved oxygen concentration and osmolarity of the cell culture medium are in principle not critical and depend on the type of cell chosen.
- the pH, temperature, dissolved oxygen concentration and osmolarity are chosen such that it is optimal for the growth and productivity of the cells.
- the person skilled in the art knows how to find the optimal pH, temperature, dissolved oxygen concentration and osmolarity for the perfusion culturing.
- the optimal pH is between 6.6 and 7.6, the optimal temperature between 30 and 39°C, the optimal osmolarity between 260 and 400mOsm/kg.
- Cells that are advantageously subjected to the process of the invention may be any cell type benefiting from this process, i.e.
- an extremely high viable cell density is a density of at least 80 x 10 6 cells per mL, preferably at least 100 x 10 6 cells per mL, more preferably at least 110 x 10 6 cells per mL, more preferably at least 120 x 10 6 cells per mL, more preferably at least 130 x 10 6 cells per mL, most preferably at least 140 x 10 6 cells per mL.
- a suitable upper limit in the cell density may lie around 500 x 10 6 cells per mL.
- the extremely high cell density of the process of the invention is accompanied by an extremly high cell viability.
- An extremely high cell viability is a viability of at least 90%, preferably at least 95%, more preferably at least 97%, most preferably at least 99%. It is to be understood that the very high viable cell density and very high cell viability are reached after a certain period of perfusion culturing, generally when the cells have reached a steady state, for mammalian cells typically 12 to 25 days after the initiation of perfusion culturing.
- the process of the invention is suitable for culturing animal cells or yeast cells, especially for culturing mammalian cells.
- the process of the invention is further especially suitable for culturing cells that easily or inherently form aggregates during culturing, especially during perfusion culturing (so-called aggregating cells).
- the process of the invention not only diminishes aggregate disposal on the filter membrane, but also diminishes aggregation of cells during the perfusion culture process, even aggregation of cells with an inherent tendency to form aggregates.
- the culturing of aggregating cells according to the invention results in a culture wherein aggregates of at least 5 cells comprise at the most 5 % of the total amount of cells, preferably at the most 4 %, more preferably at the most 3 %, even more preferably at the most 2 % of the total amount of cells.
- the culturing of aggregating cells according to the invention results in a culture that is a real single cell suspension.
- Aggregating cells are cells that form aggregates of at least 5 cells, the aggregates comprising in total at least 5 % of the total amount of cells.
- the aggregates consist of at least 6, more preferably at least 7, even more preferably at least 8, even more preferably at least 9, even more preferably at least 10 cells.
- the aggregates comprise in total at least 7%, more preferably at least 10 %, most preferably at least 15% of the total amount of cells.
- mammalian cells examples include: CHO (Chinese Hamster Ovary) cells, hybridomas, BHK (Baby Hamster Kidney) cells, myeloma cells, human cells, for example HEK-293 cells, human lymphoblastoid cells, PER.C6® cells, mouse cells, for example NS0 cells.
- yeast cells include Saccharomyces cerevisiae, Phaffia rhodozyma, Kluyveromyces lactis, or yeast cells from the genus Pichia .
- mammalian cells are used, more preferably CHO, NS0, PER.C6® cells.
- aggregating cells cells known for their aggregating behaviour during culturing.
- PER.C6® cells are used.
- Cell aggregation may for example be determined under a microscope.
- the rate of addition of cell culture medium to the culture influences the viability and the density of the cells.
- the perfusion rate is expressed in liters per day
- the SPR is the specific perfusion rate, i.e. the rate in which the cell culture medium is fed to the cell culture expressed as the volume of medium added per viable cell per time unit and wherein the viable cell density is the number of viable cells per unit of volume.
- the number of viable cells can be determined by the person skilled in the art, for example via the trypan blue exclusion method.
- the specific perfusion rate is preferably chosen between 0.01 and 0.3 nL/cell/day, more preferably between 0.01 and 0.2 nL/cell/day. It may be of advantage to take into account additional parameters when adjusting the perfusion rate, for example the amount of glucose to be fed to the culture and/or the oxygen concentration.
- the glucose perfusion rate is preferably chosen between 3 and 20 mmoles/L, more preferably between 5 and 15 mmoles/L, as part of the medium perfusion rate.
- the outflow rate of the liquid is determined by the perfusion rate and is generally chosen at an equal value.
- the outflow liquid is substantially devoid of viable cells.
- biomass i.e. cells in cell culture
- additional cell culture medium is added to the cell culture to compensate for the biomass removal. Biomass removal may lead to higher cell densities. Biomass may be removed continuously or step-wise.
- biomass is removed continuously for a defined time period. If a step-wise approach is used, biomass removal is preferably started just before or just after the cells have reached a steady state. If a step-wise approach is used, a volume of biomass of preferably between 2 and 40 % of the working volume per day, more preferably between 5 and 30% of the working volume per day, even more preferably between 10 and 25% of the working volume per day is removed per biomass removal step.
- working volume is meant the total volume of the cell culture.
- biomass removal step is meant the time from the start to the stop of the biomass removal. If a continuous approach is used, the biomass is removed continuously until the end of the cell culturing.
- the continuous removal of biomass is started just before or just after the cells have reached a steady state.
- a volume of biomass is removed of between 2 and 40 % of the working volume per day, more preferably between 3 and 30% of the working volume per day, even more preferably between 4 and 15% of the working volume per day.
- the addition of the additional cell culture medium is done to compensate for the biomass removal.
- the feed wherein additional cell culture medium is added to the cell culture may be merged into the perfusion feed, but may also be added in a separate feed.
- the person skilled in the art is aware how much additional cell culture medium is needed to compensate for the biomass removal.
- the rate of addition of the additional cell culture medium to the cell culture will be the same as the biomass removal rate.
- a biological substance is produced by the cells.
- the biological substances that can suitably be produced in the perfusion culturing of the cell are in principle all biological substances that can be produced by animal, especially mammalian, and yeast cells, for example therapeutic and diagnostic proteins, such as monoclonal antibodies, growth factors or peptide hormones, enzymes, polynucleotides, such as viral vectors used in gene therapy, vaccines, etc.
- the outflow liquid will have a lower cell density but the same concentration of the biological substance than the liquid prior to separation.
- the process according to the invention is used for the production of a biopharmaceutical product, which is a biological substance with a medical application.
- biopharmaceutical products are as follows (with examples of brand names of the corresponding biopharmaceutical product between brackets): Tenecteplase (TN KaseTM), (recombinant) antihemophilic factor (ReFactoTM), lymphoblastoid Interferon ⁇ -n1 (WellferonTM), (recombinant) Coagulation factor (NovoSevenTM), Etanercept, (EnbrelTM), Trastuzumab (HerceptinTM), Infliximab (RemicadeTM), Basiliximab (SimulectTM), Daclizumab (ZenapazTM), (recombinant) Coagulation factor IX (BenefixTM), erythropoietin alpha (Epogen®), G-CSF (Neupogen®Filgrastim), Interferon alpha-2b (Infergen®), recombinant insulin (Humulin®), Interferon beta 1a (Avonex®), Factor VIII (K
- polynucleotides with a possible medical application are gene therapeutic plasmid DNAs. Some gene therapeutic DNAs are presently tested in clinical trials for their medical application.
- vaccines are live, oral, tetravalent Rotavirus vaccine (RotaShieldTM), rabies vaccine (RanAvertTM), Hepatitis B vaccin (RECOMBIVAX HB®, Engerix®) and inactivated hepatitis A vaccine (VAQTATM).
- the biological substance in the outflow may be further purified in so-called downstream processing. Downstream processing usually comprises several purification steps in varying combinations and order. Examples of purification steps in the downstream processing are separation steps (e.g.
- Example 1 Process Optimisation of the Human Cell Line PER.C6® for the production of Biopharmaceuticals
- a perfusion culture setup was developed for the PER.C6® cell line, a human cell line that possesses a number of features that makes it favourable for the production of biopharmaceuticals.
- a perfusion setup involves the separation of various components of the culture broth so that cells are retained, harvest is captured and medium refreshment occurs. The performance of a spinfilter, an acoustic device and an Alternating Tangential Flow (ATF) unit within a continuous perfusion culture of the
- PER.C6® cell line was assessed.
- a PER.C6® cell line was used in this study that produces a human IgG. Cells were maintained in a serum free commercial medium (EX-CELLTM
- VPRO medium JRH Biosciences
- 6 mM L-glutamine Gibco
- PER.C6® cell line is a human embryonic cell-line immortalised with adenovirus type-5 (ad5) E1 gene using a phosphoglyceratekinase promoter.
- Bioreactor Set-up 1L and 4L working volume reactors (Applikon, Netherlands and B.Braun, Germany) were used during this study.
- a Braun DCU3 controller B. Braun, Germany
- Temperature was maintained at 36.5°C (range 35.5-37.5 ° C).
- Dissolved oxygen concentration was controlled at 50% (range 40-60%) of air saturation by automatic adjustment of inlet gas composition through the headspace and intermittent sparging through a microporous sparger.
- the pH setpoint was 7.1 (range 6.7-7.5) and controlled by the flow of CO 2 via the headspace.
- Cells were inoculated in the fermenter with an inoculum viable cell density range of 0.2-0.5 * 10 6 cells/mL. Perfusion started at a viable cell density in the range of 1-3*10 6 cells/mL.
- Cell Retention Cells were retained in the reactor using three different devices. First a spinfilter with a 10 ⁇ m pore size (GKD, D ⁇ ren Germany) was used. Secondly, a Biosep ADM 015 cell retention system and controller (AppliSens, the Netherlands) was used. Finally an ATF-4 control unit and housing with associate hollow fiber membrane module (Refine Technology, USA) was assessed. The hollow fiber filter used was model CFP-2-E-8SIP (0.2 micron, Area: 4600cm 2 , Amersham Bioscience obtained from Magellan instruments, USA). To maintain a constant culture volume a level sensor control loop was in operation.
- a cell count from the bioreactor was performed using the trypan blue exclusion method.
- the number of viable cells was determined as follows: An amount of cells stained with trypan blue was transferred to a Fuchs Rosenthal haemacytometer. The chamber of the haemacytometer was placed under a microscope and an appropriate number of boxes was counted. The viable cell density was calculated using the following formula:
- A number of non-stained cells in square
- B number of non-stained cells in square
- E dilution factor
- Antibody concentration was determined by a analytical protein A column using a HPLC with UV280nm absorption detection; the actual concentration was determined on basis of a calibration curve of a lgG1 reference standard.
- Figure 1 Viable cell density (x10 ⁇ 3 cells/ml) versus culture time (days) for two different continuous perfusion fermentations of an lgG1 producing PER.C6® clone using a spinfilter separation device. Stirrer speed setting of the 1 L Applikon fermenter was 100- 150rpm. The perfusion runs were performed in 1 L working volume. The specific perfusion rate (SPR) for both perfusion runs was 0.1-0.3 nL/cell/day. In both cases the perfusion runs had to be terminated because of spin filter clogging .
- Figure 2 Growth of lgG1 producing PER.C6® cells in a continuous perfusion system with an acoustic device as a cell retention system.
- Stirrer speed setting of the 1 L Applikon fermenter was 100-150rpm.
- the settings used for the run/stop cycle were 300s forward and 4.5s backwards. During the run this was adapted to a 300s/3s cycle (day 15).
- the specific perfusion rate (SPR) for the perfusion run was between 0.1-0.3 nL/cell/day.
- Figure 3 Growth of lgG1 producing PER.C6® cells in a continuous perfusion system with an ATF-4 unit as a cell retention system. The experiment was performed in a 4L Applikon fermenter. Setting for the stirrer speed was 125 rpm.
- the ATF-4 operated between 0.5 and 3 working volumes per day.
- the SPR was set at 0.03-0.08 nL/cell/day.
- the inset shows the high cell density of the culture, being completely devoid of aggregating cells.
- Figure 4 Productivity of lgG1 versus culture time (days) for two different continuous perfusion fermentations of a lgG1 producing PER.C6® clone using a spinfilter separation device.
- Figure 5 Productivity of lgG1 producing PER.C6TM cells in a continuous perfusion system with an acoustic device as a cell retention system.
- Figure 6 Productivity of lgG1 producing PER.C6® cells in a continuous perfusion system with an ATF unit as a cell retention system. Summary See Table 1 for an overview of the data obtained for the different types of perfusion.
- Table 1 Overview of the viable cell density, volumetric production rate (based on reactor volume) and the yield improvement of the perfusion runs using the three different retention devices. Batch and fed-batch results are added for comparison (data not shown).
- Example 2 Culturing of PER.C6® cells by perfusion.
- B.Braun fermenter control unit (Braun, Germany), 7L Braun vessel and headplate with associated pH, dissolved oxygen (DO) and level sensor probes (Braun, Germany), ATF-4 control unit and housing with associate hollow fiber membrane module (Refine Technology, USA).
- PER.C6® cell line expressing a model IgG was investigated in this study.
- the PER.C6® cell line is generated from retina-derived primary human cells.
- the PER.C6® cell line is able to generate complete human monoclonal antibodies (including the glycans) (ref 1, ref 2).
- Cells were cultured in shaking Erlenymer flasks at 110 rpm and 36.5°C. The headspace of these flasks was controlled using a mixture of 5% CO 2 /Air.
- Ref 1 Jones, D. H., van Berkel, P. H. O, Logtenberg, T. and Bout, A., 2002, 'PER.C6 cell line for human antibody production', Gen. Eng. News 22, 50-54.
- Ref 2 Jones, D. et al., 2003, 'High-level expression of recombinant IgG in the human cell line PER.C6', Biotechnol. Prog. 19, 163-168.
- Fermenter Cells were cultured in a fermenter where dissolved oxygen tension, pH, temperature and agitation rate were controlled as detailed below.
- Cells are inoculated in a fermenter with an inoculation viable cell density range of 0.2 - 0.5 x 10 6 cells/ml and a setpoint of 0.3 x 10 6 cells/ml. Perfusion is begun when the viable cell density > 2 x 10 6 cells /ml or at day 5 of the culture whichever is achieved first. The perfusion rate is dependent on the cell density of the culture and the rates used are described in the table below. Both the flow rate and the dilution rate are adjusted as the cell density in the fermenter increases.
- Figure 7 Culture time (days) versus flow (L/day) and specific perfusion rate (SPR in nl/cell/day) for PER.C6® cells cultured using a perfusion process.
- Figure 8 Viable cell density and cell viability using the procedure described in example 2. Table 2. Raw data obtained for example 2
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005229359A AU2005229359C1 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
PL05715787T PL1720972T3 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
SI200531842T SI1720972T1 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
EP05715787.7A EP1720972B1 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
US10/591,118 US8206981B2 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
DK05715787.7T DK1720972T3 (en) | 2004-03-05 | 2005-03-04 | METHOD OF CELL CULTIVATION USING CONTINUOUS PERFUSION AND ALTERNATIVE TANGENTIAL FLOW |
JP2007501239A JP2007525984A (en) | 2004-03-05 | 2005-03-04 | Cell culture method by continuous perfusion and alternating tangential flow |
KR1020067018075A KR101050585B1 (en) | 2004-03-05 | 2005-03-04 | Cell culture method by continuous spreading and alternating tangential flow |
ES05715787.7T ES2456015T3 (en) | 2004-03-05 | 2005-03-04 | Procedure for culturing cells by continuous perfusion and alternating tangential flow |
CNA2005800071754A CN1930281A (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
CA002557046A CA2557046A1 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
IL177724A IL177724A (en) | 2004-03-05 | 2006-08-28 | Methods for reducing the degree of aggregation of aggregating cells in a cell culture |
IL205606A IL205606A (en) | 2004-03-05 | 2010-05-06 | Perfusion cultures comprising a cell culture medium and aggregating animal cells |
US13/478,307 US20130266985A1 (en) | 2004-03-05 | 2012-05-23 | Process for Cell Culturing by Continuous Perfusion |
US14/052,878 US9260695B2 (en) | 2004-03-05 | 2013-10-14 | Process for cell culturing by continuous perfusion |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04075703.1 | 2004-03-05 | ||
EP04075702 | 2004-03-05 | ||
EP04075702.3 | 2004-03-05 | ||
EP04075703 | 2004-03-05 | ||
EP04077657 | 2004-09-27 | ||
EP04077656.9 | 2004-09-27 | ||
EP04077656 | 2004-09-27 | ||
EP04077657.7 | 2004-09-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/591,118 A-371-Of-International US8206981B2 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
US13/478,307 Continuation US20130266985A1 (en) | 2004-03-05 | 2012-05-23 | Process for Cell Culturing by Continuous Perfusion |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005095578A1 true WO2005095578A1 (en) | 2005-10-13 |
Family
ID=34961830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/002374 WO2005095578A1 (en) | 2004-03-05 | 2005-03-04 | Process for cell culturing by continuous perfusion and alternating tangential flow |
Country Status (14)
Country | Link |
---|---|
US (3) | US8206981B2 (en) |
EP (3) | EP2540815A1 (en) |
JP (6) | JP2007525984A (en) |
KR (1) | KR101050585B1 (en) |
CN (3) | CN104593277A (en) |
AU (1) | AU2005229359C1 (en) |
CA (1) | CA2557046A1 (en) |
DK (1) | DK1720972T3 (en) |
ES (1) | ES2456015T3 (en) |
IL (2) | IL177724A (en) |
PL (1) | PL1720972T3 (en) |
PT (1) | PT1720972E (en) |
SI (1) | SI1720972T1 (en) |
WO (1) | WO2005095578A1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1870450A1 (en) * | 2006-06-21 | 2007-12-26 | DSMIP Assets B.V. | Process for the culturing of E1-immortalized HER cells |
WO2008006494A1 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Improved process for the culturing of cells |
WO2010003759A2 (en) * | 2008-06-17 | 2010-01-14 | Dsm Ip Assets B.V. | Cell culturing method |
WO2011006823A1 (en) | 2009-07-16 | 2011-01-20 | Crucell Holland B.V. | Production of polio virus at high titers for vaccine production |
WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
WO2011045378A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
US20110207202A1 (en) * | 2008-11-03 | 2011-08-25 | Crucell Holland Bv | Method for the production of adenoviral vectors |
WO2011144561A1 (en) | 2010-05-18 | 2011-11-24 | Crucell Holland B.V. | Methods for welding ethylene vinyl acetate (eva) tubing, tubing obtained thereby and use of such tubing for sterile transfer of content into a bioreactor |
WO2012045769A1 (en) * | 2010-10-05 | 2012-04-12 | Novo Nordisk Health Care Ag | Process for protein production |
US8206981B2 (en) | 2004-03-05 | 2012-06-26 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
CN102762721A (en) * | 2010-02-15 | 2012-10-31 | 克鲁塞尔荷兰公司 | Method for the production of Ad26 adenoviral vectors |
US20120315696A1 (en) * | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
AU2011211462B2 (en) * | 2006-07-14 | 2013-04-18 | Dpx Holdings B.V. | Improved process for the culturing of cells |
US8679778B2 (en) | 2007-06-13 | 2014-03-25 | Cmc Biologics A/S | Method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
WO2014073967A1 (en) | 2012-11-09 | 2014-05-15 | Biosana Pty Ltd. | Discontinuous fed batch processing with the use of alternating bioreactors |
JP2014100148A (en) * | 2007-12-27 | 2014-06-05 | Baxter Internatl Inc | Cell culture processes |
WO2014160790A1 (en) * | 2013-03-26 | 2014-10-02 | Coherus Biosciences, Inc. | Protein production method |
WO2015095809A1 (en) * | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
US9587253B2 (en) | 2006-02-24 | 2017-03-07 | Toray Industries, Inc. | Method of producing chemical product with continuous fermentation and filtering |
EP2501822B1 (en) | 2009-11-17 | 2017-08-16 | E. R. Squibb & Sons, L.L.C. | Methods for enhanced protein production |
RU2668796C2 (en) * | 2013-03-15 | 2018-10-02 | Джензим Корпорейшн | Methods for creation of high density cell bank (variants) |
US10092888B2 (en) | 2014-11-07 | 2018-10-09 | Genesis Technologies, Llc | Linear reciprocating actuator |
KR20180133487A (en) * | 2016-04-14 | 2018-12-14 | 트리젤 엘티디. | Fixed-bed bioreactor with constant flow pump / tubing system |
EP3152317B1 (en) | 2014-06-04 | 2019-01-02 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
US10213508B2 (en) | 2011-10-18 | 2019-02-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with xylitol |
WO2019055796A1 (en) * | 2017-09-15 | 2019-03-21 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
US10294460B2 (en) | 2014-07-24 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Process for the purification of poliovirus from cell cultures |
US10421986B2 (en) | 2013-09-30 | 2019-09-24 | Janssen Vaccines & Prevention B.V. | Method for the clarification of high-density crude cell culture harvest |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
WO2020165873A1 (en) * | 2019-02-15 | 2020-08-20 | Oncosimis Biotech Private Limited | Method and system for enhanced continuous production, secretion and separation of recombinant polypeptides from bacteria |
EP2976418B1 (en) | 2013-03-19 | 2020-09-30 | CMC Biologics A/S | A method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process. |
US10822429B2 (en) | 2012-07-09 | 2020-11-03 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
US10947306B2 (en) | 2012-09-11 | 2021-03-16 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
US11193103B2 (en) | 2017-10-16 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Perfusion bioreactor and related methods of use |
WO2022027013A1 (en) | 2020-07-28 | 2022-02-03 | Seagen Inc. | Methods and systems for producing polypeptides |
US11242504B2 (en) | 2016-04-14 | 2022-02-08 | Trizell Ltd. | Aseptic bioreactor sampling system |
US11492578B2 (en) | 2016-06-30 | 2022-11-08 | Fujifilm Corporation | Membrane separation method of cell suspension, and cell culture device |
EP3626737B1 (en) * | 2011-05-13 | 2023-11-29 | Octapharma AG | A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102282249A (en) | 2008-09-02 | 2011-12-14 | 普拉里斯坦有限公司 | Adherent cells from placenta tissue and use thereof in therapy |
CN107988166B (en) * | 2011-07-01 | 2022-03-15 | 美国安进公司 | Mammalian cell culture |
CN103305417A (en) * | 2012-03-07 | 2013-09-18 | 无锡药明康德生物技术有限公司 | High-yield reactor for protein production, and production method and application thereof |
GB201211256D0 (en) | 2012-06-25 | 2012-08-08 | Glaxosmithkline Biolog Sa | Fermentation process |
EP2900804B1 (en) | 2012-09-27 | 2019-09-18 | GE Healthcare Bio-Sciences AB | Tangential flow perfusion system |
US9790465B2 (en) | 2013-04-30 | 2017-10-17 | Corning Incorporated | Spheroid cell culture well article and methods thereof |
AU2014318420B2 (en) * | 2013-09-16 | 2020-01-16 | Genzyme Corporation | Methods and systems for processing a cell culture |
CN103525756B (en) * | 2013-10-23 | 2015-04-08 | 南京农业大学 | Method for separating and culturing primary chicken hepatocytes |
SG10201912081RA (en) * | 2014-01-29 | 2020-02-27 | Amgen Inc | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
CN106414490A (en) * | 2014-02-17 | 2017-02-15 | 爱德技术生物科学有限公司 | Enhancement of recombinant protein expression using a membrane-based cell retention system |
JP6530171B2 (en) * | 2014-09-09 | 2019-06-12 | 旭化成メディカル株式会社 | Method of collecting culture product |
JP6930914B2 (en) | 2014-10-29 | 2021-09-01 | コーニング インコーポレイテッド | Perfusion bioreactor platform |
SG11201703493SA (en) | 2014-10-29 | 2017-05-30 | Corning Inc | Cell culture insert |
CN107532132A (en) * | 2015-02-09 | 2018-01-02 | 优尼沃赛尔斯公司 | For producing the systems, devices and methods of cell and/or cell products |
AU2017249402A1 (en) | 2016-04-12 | 2018-10-04 | Artemis Biosystems, Inc. | Perfusion filtration systems |
EP3443064A1 (en) * | 2016-04-15 | 2019-02-20 | Boehringer Ingelheim International GmbH | Cell retention device and method |
US20200080050A1 (en) * | 2016-07-11 | 2020-03-12 | Yaakov Nahmias | Systems and methods for growing cells in vitro |
JP7245222B2 (en) | 2017-07-14 | 2023-03-23 | コーニング インコーポレイテッド | 3D cell culture vessel for manual or automatic medium exchange |
US11857970B2 (en) | 2017-07-14 | 2024-01-02 | Corning Incorporated | Cell culture vessel |
WO2019014610A1 (en) | 2017-07-14 | 2019-01-17 | Corning Incorporated | Cell culture vessel for 3d culture and methods of culturing 3d cells |
CN111065729B (en) | 2017-07-14 | 2024-04-26 | 康宁股份有限公司 | Cell culture vessel |
CN111051496B (en) | 2017-09-06 | 2024-03-08 | 富士胶片株式会社 | Method for producing product |
CN111344558A (en) | 2017-10-06 | 2020-06-26 | 龙沙有限公司 | Automated control of cell culture using raman spectroscopy |
BR112020011627A2 (en) * | 2017-12-11 | 2020-11-17 | Amgen Inc. | continuous manufacturing process for bispecific antibody products |
AU2019231885B2 (en) | 2018-03-08 | 2022-03-24 | Repligen Corporation | Tangential flow depth filtration systems and methods of filtration using same |
CN110241012B (en) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | Production method and production module for upstream staged interception of biomacromolecules and application of production module in production |
CN111868249A (en) * | 2018-03-19 | 2020-10-30 | 富士胶片株式会社 | Method for producing product |
AU2019273030B2 (en) | 2018-05-25 | 2022-08-18 | Repligen Corporation | Tangential flow filtration systems and methods |
CN108504562A (en) * | 2018-06-21 | 2018-09-07 | 江苏澳创生物科技有限公司 | A kind of system of production of L-threonine by fermentation and its application |
WO2020013845A1 (en) | 2018-07-13 | 2020-01-16 | Corning Incorporated | Cell culture vessels with stabilizer devices |
CN111065725B (en) | 2018-07-13 | 2024-03-29 | 康宁股份有限公司 | Fluidic device comprising microplates with interconnected walls |
JP7171695B2 (en) | 2018-07-13 | 2022-11-15 | コーニング インコーポレイテッド | A microcavity dish having sidewalls containing a liquid medium delivery surface |
CN114127260A (en) * | 2019-07-16 | 2022-03-01 | 信达生物制药(苏州)有限公司 | Cell culture method for high-density continuous inoculation and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005145A1 (en) | 1991-08-30 | 1993-03-18 | Celltech Limited | Cell culture process and medium for the growth of adherent animal cells |
US20030054544A1 (en) * | 2001-09-14 | 2003-03-20 | Medcell Biologics, Inc. | Oxygen enriched bioreactor and method of culturing cells |
US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US54544A (en) * | 1866-05-08 | Improvement in low-water detecters | ||
JPS61199788A (en) | 1985-02-28 | 1986-09-04 | Mitsubishi Rayon Co Ltd | Separation and concentration of fermentation product, and method for continuous fermentation |
US5286646A (en) | 1985-11-25 | 1994-02-15 | Boehringer Mannheim Gmbh | Method for mammalian cell culture |
GB8617646D0 (en) | 1986-07-18 | 1986-08-28 | Manchester Inst Science Tech | Recovery of biological material |
US4806484A (en) | 1987-08-07 | 1989-02-21 | Igb Products, Ltd. | Perfusion airlift bioreactor |
JPH0797982B2 (en) | 1987-09-24 | 1995-10-25 | 東洋紡績株式会社 | Cell culture device |
US4921792A (en) * | 1987-11-27 | 1990-05-01 | Miles Inc. | Continuous cell dispersion, cultivation and substance recovery process |
JPH01243985A (en) | 1988-03-25 | 1989-09-28 | P C C Technol:Kk | Method for culturing plant organ and culture vessel therefor |
US5595909A (en) * | 1988-05-23 | 1997-01-21 | Regents Of The University Of Minnesota | Filter device |
DE68917642T2 (en) | 1988-05-25 | 1995-02-09 | Teijin Ltd | Process for the continuous cultivation of adherent animal cells. |
JPH02113896A (en) * | 1988-10-24 | 1990-04-26 | Snow Brand Milk Prod Co Ltd | Human anti-ricin monoclonal antibody and hybridoma secreting same antibody |
US5019512A (en) * | 1989-03-17 | 1991-05-28 | Baxter International Inc. | Spin filter for removing substantially cell-free culture medium from suspension cell culture system |
JPH0541984A (en) * | 1990-09-07 | 1993-02-23 | Dow Chem Co:The | Cell multiplication in hollow fiber in stirring container |
US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
JPH05153973A (en) | 1991-12-03 | 1993-06-22 | Hitachi Ltd | Cell culture method and apparatus therefor |
US6204000B1 (en) | 1995-04-28 | 2001-03-20 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 |
JP2752918B2 (en) * | 1995-05-16 | 1998-05-18 | ユーエイチティー株式会社 | Microcarrier culture method for animal cells |
US6001585A (en) | 1997-11-14 | 1999-12-14 | Cellex Biosciences, Inc. | Micro hollow fiber bioreactor |
JP2997771B2 (en) * | 1998-06-29 | 2000-01-11 | 金沢大学長 | Cell suspension culture method |
US8026096B1 (en) * | 1998-10-08 | 2011-09-27 | Protein Sciences Corporation | In vivo active erythropoietin produced in insect cells |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
CA2252972C (en) | 1998-11-26 | 2012-09-18 | National Research Council Of Canada | Serum-free production of recombinant proteins and adenoviral vectors |
ES2319254T3 (en) | 1999-01-26 | 2009-05-06 | Schering-Plough Ltd. | PROPAGATION OF BOVINE CORONAVIRUS IN OVARY CELLS OF CHINESE HAMSTER |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
ATE447617T1 (en) | 1999-04-15 | 2009-11-15 | Crucell Holland Bv | USE OF RECOMBINANT PROTEINS IN HUMAN CELLS |
JP2001149099A (en) | 1999-11-26 | 2001-06-05 | Olympus Optical Co Ltd | Preparation of specimen of nucleus-containing cell for analysis of chromosome abnormality |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
JP4138209B2 (en) | 2000-06-29 | 2008-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Pravastatin-containing composition |
JP2002113896A (en) | 2000-10-05 | 2002-04-16 | Seiko Epson Corp | Imaging apparatus |
WO2002086133A1 (en) * | 2001-04-17 | 2002-10-31 | Seiren Kabushiki Kaisha | Medium additives and media for culturing animal cells |
DE10120835C2 (en) | 2001-04-27 | 2003-04-10 | Sifin Inst Fuer Immunpraeparat | Process for the production of monoclonal antibodies |
CA2351156A1 (en) | 2001-07-04 | 2003-01-04 | Peter W. Zandstra | A bioprocess for the generation of pluripotent cell derived cells and tissues |
AU2002333739B2 (en) * | 2001-08-31 | 2007-08-02 | Bayer Intellectual Property Gmbh | A unit and a process for carrying out high cell density fermentation |
JP3968347B2 (en) | 2001-09-05 | 2007-08-29 | ヤマサ醤油株式会社 | Pharmaceutical composition for diabetic neuropathy |
JP2003219873A (en) | 2002-01-24 | 2003-08-05 | Japan Science & Technology Corp | Immortalized cell derived from chinook salmon of salmonidae |
US20030186335A1 (en) | 2002-03-28 | 2003-10-02 | National Institute Of Advanced Industrial Science And Technology | Monoclonal antibodies, hybridomas, cell isolation method, isolated cells and immunological diagnostic method |
DE10237082B4 (en) * | 2002-08-09 | 2014-12-31 | Sartorius Stedim Biotech Gmbh | Method and device for the biotechnological production of recyclables |
CN101328473B (en) | 2003-05-09 | 2012-05-02 | 克鲁塞尔荷兰公司 | Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom |
JP2005041984A (en) | 2003-07-22 | 2005-02-17 | Shin Kobe Electric Mach Co Ltd | Method of manufacturing water-crosslinking polyolefin sheet |
EP2540815A1 (en) | 2004-03-05 | 2013-01-02 | DSM IP Assets B.V. | Perfusion cell culture |
PL2343362T3 (en) * | 2006-07-14 | 2016-11-30 | Improved process for the culturing of cells | |
JP2008308560A (en) | 2007-06-13 | 2008-12-25 | Tohcello Co Ltd | Method for producing surface stain resistant composite film |
-
2005
- 2005-03-04 EP EP12186351A patent/EP2540815A1/en not_active Ceased
- 2005-03-04 EP EP10183651A patent/EP2308958A3/en not_active Withdrawn
- 2005-03-04 WO PCT/EP2005/002374 patent/WO2005095578A1/en active Application Filing
- 2005-03-04 ES ES05715787.7T patent/ES2456015T3/en active Active
- 2005-03-04 CN CN201410471955.5A patent/CN104593277A/en active Pending
- 2005-03-04 CA CA002557046A patent/CA2557046A1/en not_active Withdrawn
- 2005-03-04 CN CNA2005800071754A patent/CN1930281A/en active Pending
- 2005-03-04 SI SI200531842T patent/SI1720972T1/en unknown
- 2005-03-04 US US10/591,118 patent/US8206981B2/en active Active
- 2005-03-04 KR KR1020067018075A patent/KR101050585B1/en active IP Right Review Request
- 2005-03-04 DK DK05715787.7T patent/DK1720972T3/en active
- 2005-03-04 PT PT57157877T patent/PT1720972E/en unknown
- 2005-03-04 PL PL05715787T patent/PL1720972T3/en unknown
- 2005-03-04 CN CN201410601800.9A patent/CN104388324A/en active Pending
- 2005-03-04 EP EP05715787.7A patent/EP1720972B1/en not_active Revoked
- 2005-03-04 AU AU2005229359A patent/AU2005229359C1/en not_active Ceased
- 2005-03-04 JP JP2007501239A patent/JP2007525984A/en active Pending
-
2006
- 2006-08-28 IL IL177724A patent/IL177724A/en unknown
-
2010
- 2010-05-06 IL IL205606A patent/IL205606A/en unknown
-
2011
- 2011-02-22 JP JP2011036102A patent/JP2011125348A/en active Pending
- 2011-11-28 JP JP2011259168A patent/JP2012090632A/en active Pending
-
2012
- 2012-05-23 US US13/478,307 patent/US20130266985A1/en not_active Abandoned
-
2013
- 2013-10-14 US US14/052,878 patent/US9260695B2/en active Active
-
2014
- 2014-01-31 JP JP2014016778A patent/JP5719947B2/en not_active Expired - Fee Related
-
2015
- 2015-10-26 JP JP2015209828A patent/JP2016039817A/en active Pending
-
2017
- 2017-07-06 JP JP2017132997A patent/JP2017225443A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005145A1 (en) | 1991-08-30 | 1993-03-18 | Celltech Limited | Cell culture process and medium for the growth of adherent animal cells |
US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
US20030054544A1 (en) * | 2001-09-14 | 2003-03-20 | Medcell Biologics, Inc. | Oxygen enriched bioreactor and method of culturing cells |
Non-Patent Citations (13)
Title |
---|
BANIK G.G., HEATH C.A.: "Partial and total cell retention in a filtration-based homogeneous perfusion reactor", BIOTECHNOL. PROG., vol. 11, 1995, pages 584 - 588, XP002332439 * |
DOYLE, A.; GRIFFITHS, J. B.; NEWELL, D. G.: "Cell &Tissue culture: Laboratory Procedures", 1993, JOHN WILEY & SONS |
FRESHNEY, R.: "Culture of animal cells", 2000, WILEY-LISS |
FUREY, J.: "Continuous Cell Culture Using the ATF System", GENETIC ENGINEERING NEWS, vol. 20, no. 10, 15 May 2000 (2000-05-15), pages 52 - 53, XP002317547 * |
J. FUREY: "Continuous Cell Culture Using the ATF System", GENETIC ENGINEERING NEWS, vol. 20, no. 10, 15 May 2000 (2000-05-15), pages 52 - 53 |
JONES D H ET AL: "PER.C6 CELL LINE FOR HUMAN ANTIBODY PRODUCTION CRUCELL'S TECHNOLOGY MAINTAINS HUMAN GLYCOSYLATION PATTERNS", GENETIC ENGINEERING NEWS, MARY ANN LIEBERT, NEW YORK, US, vol. 22, no. 10, 15 May 2002 (2002-05-15), pages 50,54, XP009018783, ISSN: 1270-6377 * |
JORJANI, P. AND OZTURK S.S.: "Effects of cell density and temperature on oxygen consumption rate for different mammalian cell lines", BIOTECHNOLOGY AND BIOENGINEERING, vol. 64, no. 3, 5 August 1999 (1999-08-05), pages 349 - 356, XP002332438 * |
KYUNG ET AL., CYTOTECHNOLOGY, vol. 14, 1994, pages 183 - 190 |
See also references of EP1720972A1 |
VELEZ D ET AL: "USE OF TANGENTIAL FLOW FILTRATION IN PERFUSION PROPAGATION OF HYBRIDOMA CELLS FOR PRODUCTION OF MONOCLONAL ANTIBODIES", BIOTECHNOLOGY AND BIOENGINEERING. INCLUDING: SYMPOSIUM BIOTECHNOLOGY IN ENERGY PRODUCTION AND CONSERVATION, JOHN WILEY & SONS. NEW YORK, US, vol. 33, no. 7, 20 February 1989 (1989-02-20), pages 938 - 940, XP000005263, ISSN: 0006-3592 * |
VOISARD D ET AL: "Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells.", BIOTECHNOLOGY AND BIOENGINEERING, vol. 82, no. 7, 30 June 2003 (2003-06-30), pages 751 - 765, XP002317548, ISSN: 0006-3592 * |
VOISIER ET AL., BIOTECHNOL. BIOENG., vol. 82, 2003, pages 751 - 765 |
WOODSIDE S M ET AL: "Mammalian cell retention devices for stirred perfusion bioreactors", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 28, no. 1-3, 1998, pages 163 - 175, XP002301951, ISSN: 0920-9069 * |
Cited By (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9260695B2 (en) | 2004-03-05 | 2016-02-16 | Dpx Holdings B.V. | Process for cell culturing by continuous perfusion |
US8206981B2 (en) | 2004-03-05 | 2012-06-26 | Dsm Ip Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
EP1988170B1 (en) | 2006-02-24 | 2019-05-01 | Toray Industries, Inc. | Method of producing chemical product and continuous fermentation apparatus |
US9587253B2 (en) | 2006-02-24 | 2017-03-07 | Toray Industries, Inc. | Method of producing chemical product with continuous fermentation and filtering |
EP1870450A1 (en) * | 2006-06-21 | 2007-12-26 | DSMIP Assets B.V. | Process for the culturing of E1-immortalized HER cells |
AU2011211462B2 (en) * | 2006-07-14 | 2013-04-18 | Dpx Holdings B.V. | Improved process for the culturing of cells |
WO2008006494A1 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Improved process for the culturing of cells |
EP2343362B2 (en) † | 2006-07-14 | 2024-04-03 | Patheon Holdings I B.V. | Improved process for the culturing of cells |
JP2009543565A (en) * | 2006-07-14 | 2009-12-10 | ディーエスエム アイピー アセッツ ビー.ブイ. | Improved method of culturing cells |
EP2343362A1 (en) | 2006-07-14 | 2011-07-13 | DSM IP Assets B.V. | Improved process for the culturing of cells |
TWI512102B (en) * | 2006-07-14 | 2015-12-11 | Dpx Holdings Bv | Improved process for the culturing of cells |
AU2007272054B2 (en) * | 2006-07-14 | 2011-09-08 | Dpx Holdings B.V. | Improved process for the culturing of cells |
EP2041259B1 (en) | 2006-07-14 | 2015-10-14 | DPx Holdings B.V. | Improved process for the culturing of cells |
US8119368B2 (en) | 2006-07-14 | 2012-02-21 | Dsm Ip Assets B.V. | Process for the culturing of cells |
TWI627274B (en) * | 2006-07-14 | 2018-06-21 | 荷蘭商培森控股公司 | Improved process for the culturing of cells |
US8440458B2 (en) | 2006-07-14 | 2013-05-14 | Dsm Ip Assets B.V. | Process for the culturing of cells |
EA016451B1 (en) * | 2006-07-14 | 2012-05-30 | ДСМ АйПи АССЕТС Б.В. | Improved process for the suspension culturing of cells |
EP2634242B1 (en) | 2006-07-14 | 2017-04-05 | Patheon Holdings I B.V. | Improved process for the culturing of cells |
US8222001B2 (en) | 2006-07-14 | 2012-07-17 | Dsm Ip Assets B.V. | Process for the culturing of cells |
JP2012165764A (en) * | 2006-07-14 | 2012-09-06 | Dsm Ip Assets Bv | Improved process for culturing cell |
EP2634243B1 (en) | 2006-07-14 | 2017-09-06 | Patheon Holdings I B.V. | Improved process for the culturing of cells |
US9670520B2 (en) | 2006-07-14 | 2017-06-06 | Patheon Holdings | B.V. | Process for the culturing of cells |
CN102876628A (en) * | 2006-07-14 | 2013-01-16 | 帝斯曼知识产权资产管理有限公司 | Improved process for the culturing of cells |
KR20130014640A (en) * | 2006-07-14 | 2013-02-07 | 디에스엠 아이피 어셋츠 비.브이. | Improved process for the culturing of cells |
EP2343362B1 (en) | 2006-07-14 | 2016-03-30 | DPx Holdings B.V. | Improved process for the culturing of cells |
KR101143796B1 (en) * | 2006-07-14 | 2012-05-21 | 디에스엠 아이피 어셋츠 비.브이. | Improved process for the culturing of cells |
AU2013204016B2 (en) * | 2006-07-14 | 2015-06-04 | Dpx Holdings B.V. | Improved process for the culturing of cells |
US9469865B2 (en) | 2006-07-14 | 2016-10-18 | Dpx Holdings B.V. | Process for the culturing of cells |
EP2634250B1 (en) | 2006-07-14 | 2017-04-05 | Patheon Holdings I B.V. | Improved process for the culturing of cells |
EP2634243A1 (en) | 2006-07-14 | 2013-09-04 | DSM IP Assets B.V. | Improved process for the culturing of cells |
EP2634242A1 (en) | 2006-07-14 | 2013-09-04 | DSM IP Assets B.V. | Improved process for the culturing of cells |
EP2634250A1 (en) | 2006-07-14 | 2013-09-04 | DSM IP Assets B.V. | Improved process for the culturing of cells |
AU2011211462C1 (en) * | 2006-07-14 | 2015-01-22 | Dpx Holdings B.V. | Improved process for the culturing of cells |
TWI413689B (en) * | 2006-07-14 | 2013-11-01 | Dsm Ip Assets Bv | Improved process for the culturing of cells |
CN104263700A (en) * | 2006-07-14 | 2015-01-07 | 帝斯曼知识产权资产管理有限公司 | Improved Process For The Culturing Of Cells |
US8685731B2 (en) | 2006-07-14 | 2014-04-01 | Dsm Ip Assets B.V. | Process for the culturing of cells |
JP2011067222A (en) * | 2006-07-14 | 2011-04-07 | Dsm Ip Assets Bv | Improved process for culturing of cell |
JP2014217395A (en) * | 2006-07-14 | 2014-11-20 | ディーエスエム アイピー アセッツ ビー.ブイ. | Improved process for culturing cells |
AU2007272054C1 (en) * | 2006-07-14 | 2014-08-28 | Dpx Holdings B.V. | Improved process for the culturing of cells |
KR101685246B1 (en) | 2006-07-14 | 2016-12-09 | 디피엑스 홀딩스 비.브이. | Improved process for the culturing of cells |
US8679778B2 (en) | 2007-06-13 | 2014-03-25 | Cmc Biologics A/S | Method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
JP2014100148A (en) * | 2007-12-27 | 2014-06-05 | Baxter Internatl Inc | Cell culture processes |
WO2010003759A3 (en) * | 2008-06-17 | 2010-03-04 | Dsm Ip Assets B.V. | Cell culturing method |
WO2010003759A2 (en) * | 2008-06-17 | 2010-01-14 | Dsm Ip Assets B.V. | Cell culturing method |
US10041049B2 (en) * | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
US20110207202A1 (en) * | 2008-11-03 | 2011-08-25 | Crucell Holland Bv | Method for the production of adenoviral vectors |
US8546123B2 (en) | 2009-07-16 | 2013-10-01 | Crucell Holland B.V. | Production of poliovirus at high titers for vaccine production |
US9022240B2 (en) | 2009-07-16 | 2015-05-05 | Crucell Holland B.V. | Production of poliovirus at high titers for vaccine production |
WO2011006823A1 (en) | 2009-07-16 | 2011-01-20 | Crucell Holland B.V. | Production of polio virus at high titers for vaccine production |
US8460920B2 (en) | 2009-10-15 | 2013-06-11 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
WO2011045378A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
US8470585B2 (en) | 2009-10-15 | 2013-06-25 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
EP3431608A3 (en) * | 2009-11-17 | 2019-02-20 | E. R. Squibb & Sons, L.L.C. | Method for enhanced protein production |
EP3431608A2 (en) | 2009-11-17 | 2019-01-23 | E. R. Squibb & Sons, L.L.C. | Method for enhanced protein production |
EP2501822B1 (en) | 2009-11-17 | 2017-08-16 | E. R. Squibb & Sons, L.L.C. | Methods for enhanced protein production |
CN102762721A (en) * | 2010-02-15 | 2012-10-31 | 克鲁塞尔荷兰公司 | Method for the production of Ad26 adenoviral vectors |
CN102762721B (en) * | 2010-02-15 | 2015-03-11 | 克鲁塞尔荷兰公司 | Method for the production of Ad26 adenoviral vectors |
US20120315696A1 (en) * | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
WO2011144561A1 (en) | 2010-05-18 | 2011-11-24 | Crucell Holland B.V. | Methods for welding ethylene vinyl acetate (eva) tubing, tubing obtained thereby and use of such tubing for sterile transfer of content into a bioreactor |
CN103154233A (en) * | 2010-10-05 | 2013-06-12 | 诺沃—诺迪斯克保健股份有限公司 | Process for protein production |
EP2957628A1 (en) * | 2010-10-05 | 2015-12-23 | Novo Nordisk Health Care AG | Process for protein production |
WO2012045769A1 (en) * | 2010-10-05 | 2012-04-12 | Novo Nordisk Health Care Ag | Process for protein production |
US10138290B2 (en) | 2010-10-05 | 2018-11-27 | Novo Nordisk Healthcare Ag | Process for protein production |
EP3626737B1 (en) * | 2011-05-13 | 2023-11-29 | Octapharma AG | A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii |
US10213508B2 (en) | 2011-10-18 | 2019-02-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with xylitol |
US10772963B2 (en) | 2011-10-18 | 2020-09-15 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with xylitol |
US11000588B2 (en) | 2011-10-18 | 2021-05-11 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
US10293049B2 (en) | 2011-10-18 | 2019-05-21 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with amino acids |
US11129876B2 (en) | 2011-10-18 | 2021-09-28 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with amino acids |
US10822429B2 (en) | 2012-07-09 | 2020-11-03 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
US10954295B2 (en) | 2012-09-11 | 2021-03-23 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
US10947306B2 (en) | 2012-09-11 | 2021-03-16 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
US11001627B2 (en) | 2012-09-11 | 2021-05-11 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
US10954293B2 (en) | 2012-09-11 | 2021-03-23 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
US10954294B2 (en) | 2012-09-11 | 2021-03-23 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
WO2014073967A1 (en) | 2012-11-09 | 2014-05-15 | Biosana Pty Ltd. | Discontinuous fed batch processing with the use of alternating bioreactors |
RU2668796C2 (en) * | 2013-03-15 | 2018-10-02 | Джензим Корпорейшн | Methods for creation of high density cell bank (variants) |
EP2976418B1 (en) | 2013-03-19 | 2020-09-30 | CMC Biologics A/S | A method for producing a product (e.g. polypeptide) in a continuous cell culture fermentation process. |
EP3391942A1 (en) * | 2013-03-26 | 2018-10-24 | Coherus Biosciences, Inc. | Protein production method |
US10975138B2 (en) | 2013-03-26 | 2021-04-13 | Coherus Biosciences, Inc. | Correctly folded etanercept composition |
EP2978498A4 (en) * | 2013-03-26 | 2016-10-05 | Coherus Biosciences Inc | Protein production method |
AU2019201129B2 (en) * | 2013-03-26 | 2020-12-24 | Coherus Biosciences, Inc. | Protein production method |
WO2014160790A1 (en) * | 2013-03-26 | 2014-10-02 | Coherus Biosciences, Inc. | Protein production method |
AU2014241259B2 (en) * | 2013-03-26 | 2018-12-06 | Coherus Biosciences, Inc. | Protein production method |
AU2014241259B9 (en) * | 2013-03-26 | 2018-12-20 | Coherus Biosciences, Inc. | Protein production method |
US10421986B2 (en) | 2013-09-30 | 2019-09-24 | Janssen Vaccines & Prevention B.V. | Method for the clarification of high-density crude cell culture harvest |
WO2015095809A1 (en) * | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
EP3152317B1 (en) | 2014-06-04 | 2019-01-02 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
US11384378B2 (en) | 2014-06-04 | 2022-07-12 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
US11427848B2 (en) | 2014-06-04 | 2022-08-30 | Amgen Inc. | Methods for harvesting mammalian cell cultures |
US10294460B2 (en) | 2014-07-24 | 2019-05-21 | Janssen Vaccines & Prevention B.V. | Process for the purification of poliovirus from cell cultures |
US10092888B2 (en) | 2014-11-07 | 2018-10-09 | Genesis Technologies, Llc | Linear reciprocating actuator |
US11781102B2 (en) | 2016-04-14 | 2023-10-10 | Trizell Ltd. | Large-scale PEI-mediated plasmid transfection |
US11242504B2 (en) | 2016-04-14 | 2022-02-08 | Trizell Ltd. | Aseptic bioreactor sampling system |
US11261416B2 (en) | 2016-04-14 | 2022-03-01 | Trizell Ltd. | Fixed-bed bioreactor with constant-flow pump / tubing system |
KR102535013B1 (en) * | 2016-04-14 | 2023-05-22 | 트리젤 엘티디. | Fixed bed bioreactor with constant flow pump/tubing system |
KR20180133487A (en) * | 2016-04-14 | 2018-12-14 | 트리젤 엘티디. | Fixed-bed bioreactor with constant flow pump / tubing system |
US11492578B2 (en) | 2016-06-30 | 2022-11-08 | Fujifilm Corporation | Membrane separation method of cell suspension, and cell culture device |
WO2019055796A1 (en) * | 2017-09-15 | 2019-03-21 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
CN111868223A (en) * | 2017-09-15 | 2020-10-30 | 百时美施贵宝公司 | Online biomass capacitance monitoring during large-scale production of target polypeptides |
US11193103B2 (en) | 2017-10-16 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Perfusion bioreactor and related methods of use |
US11965153B2 (en) | 2017-10-16 | 2024-04-23 | Regeneron Pharmaceuticals, Inc. | Perfusion bioreactor and related methods of use |
WO2020165873A1 (en) * | 2019-02-15 | 2020-08-20 | Oncosimis Biotech Private Limited | Method and system for enhanced continuous production, secretion and separation of recombinant polypeptides from bacteria |
WO2022027013A1 (en) | 2020-07-28 | 2022-02-03 | Seagen Inc. | Methods and systems for producing polypeptides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9260695B2 (en) | Process for cell culturing by continuous perfusion | |
US9670520B2 (en) | Process for the culturing of cells | |
AU2013203993C1 (en) | Process for cell culturing by continuous perfusion and alternating tangential flow |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005715787 Country of ref document: EP Ref document number: 2557046 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 177724 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005229359 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007501239 Country of ref document: JP Ref document number: 1020067018075 Country of ref document: KR Ref document number: 200580007175.4 Country of ref document: CN Ref document number: 5130/DELNP/2006 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005229359 Country of ref document: AU Date of ref document: 20050304 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005229359 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005715787 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067018075 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10591118 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10591118 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 205606 Country of ref document: IL |